Minovia Therapeutics treats mitochondrial diseases through cell therapy using its Mitochondrial Augmentation Therapy (MAT) platform.

The companys initial clinical focus is on rare mitochondrial diseases for which there are no approved treatments.

The company developed a cell therapy approach to treat a broad range of indications generated by a mitochondrial dysfunction.

Using its proprietary Mitochondrial Augmentation Technology (MAT), designed to be a robust therapeutic platform combining personalized mitochondrial cell therapy and scalable manufacturing processes, Minovia is advancing breakthrough therapies for patients with mitochondrial dysfunction, caused by disease as well as during aging.Minovia is currently conducting a phase 1/2 clinical trial in patients with Pearson Syndrome.